US FDA seeks more data for Covaxin launch

June 11, 2021 13:42

Jab we met

In setback that could potentially delay the launch of Bharat Biotech's Covid-19 vaccine Covaxin in USA, the Food and Drug Administration there has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixing hopes of Emergency Use Authorisation.

Ocugen in a statement on Thursday announced that as recommended by the FDA, it will pursue submission of a biologics licence application (BLA) for Covaxin.

BLA is a "full approval" mechanism by the FDA for drugs and vaccines. The development may delay the Covaxin launch in the US, Ocugen said.

"The company will no longer pursue an Emergency Use Authorization (EUA) for Covaxin. The FDA provided feedback to Ocugen regarding the Master File. The company had previously submitted and recommended that Ocugen pursue a BLA submission instead of an EUA application for its vaccine candidate and requested additional information and data," Ocugen said. Ocugen is in discussions with the FDA to understand the additional information required to support a BLA submission.

The company anticipates that data from an additional clinical trial will be required to support the submission. "Although we were close to finalising our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path. While this will extend our timelines, we are committed to bringing Covaxin to the US," Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer and co-founder of Ocugen said.

"This differentiated vaccine is a critical tool to include in our national arsenal given its potential to address the SARS-CoV-2 variants, including the delta variant, and given the unknowns about what will be needed to protect US population in the long term," he added.

Reacting to the FDA's "recommendation", Bharat Biotech said with good herd immunity and significant percentage of the population vaccinated, the pandemic is reducing in the United States, the US regulator had earlier communicated that no new EUAs will be approved for COVID-19 vaccines.

« Back to LIVE

TOP STORIES

CSK Vs LSG: Who Bowled Best? Vote!

Krunal Pandya emerged as the wrecker-in-chief on Friday night.

'It was world-class batsmanship from Rahul and de Kock'

Lucknow Super Giants pacer Matt Henry was in awe of the "world-class batsmanship" of skipper KL Rahul and Quinton de Kock, saying the century-plus opening stand between the duo helped them outclass a "very good" Chennai Super Kings...

IRDAI removes age limits on health insurance, huge relief for seniors

The move by the insurance regulatory body aims to create a more inclusive healthcare ecosystem in India and to encourage insurance provider companies to diversify their product offerings.

Rahul, Ruturaj fined Rs 12 lakh each for slow over-rate

Lucknow Super Giants skipper KL Rahul and his Chennai Super Kings counterpart Ruturaj Gaikwad have been fined Rs 12 lakh each as their teams maintained a slow over-rate in their Indian Premier League match in Lucknow on Friday.

Phase 1: Voter turnout may cross 64%, Tripura tops with 80.17%

According to an official release, the voting percentage is likely to go up when reports from all polling stations are obtained, as polling was scheduled until 6 pm in many constituencies.